首页 › 原发性血小板增多症 › 纽约州 › New York City
New York City NY 原发性血小板增多症临床试验
7项针对 原发性血小板增多症的研究正在 New York City及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
招募中2 期
- NYP/Weill Cornell Medical Center, New York
A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia
招募中3 期
- Icahn School of Medicine At Mount Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
- Weill Cornell Medical College - Newyork-Presbyterian Hospita, New York
A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
招募中1 期
- Icahn School of Medicine At Mount Sinai, New York
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
招募中1 期
- Memorial Sloan Kettering Cancer Center, New York
- Mount Sinai School of Medicine, New York
- Weill Cornell Medicine, New York
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
招募中1 期
- Icahn School of Medicine At Mount Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)
招募中观察性研究
- Memorial Sloan Kettering Cancer Center, New York
MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) Trial
招募中2 期
- Ruttenberg Treatment Center, New York
其他城市的 原发性血小板增多症试验
- Durham, NC6 项研究
- Chicago, IL4 项研究
- Mountain View, CA4 项研究
- Baltimore, MD4 项研究
- Nashville, TN4 项研究
- Miami, FL4 项研究
- Salt Lake City, UT4 项研究
- Boston, MA4 项研究
- Irvine, CA3 项研究
- Los Angeles, CA3 项研究
- Houston, TX3 项研究
- Cleveland, OH3 项研究
New York City的其他研究
- 乳腺癌136 项研究
- 非小细胞肺癌121 项研究
- 癌症（所有类型）109 项研究
- 前列腺癌103 项研究
- 转移性癌症93 项研究
- 结直肠癌78 项研究
- 卵巢癌69 项研究
- 肺癌60 项研究
- 多发性骨髓瘤60 项研究
- 胰腺癌60 项研究
- 子宫内膜癌52 项研究
- 急性髓系白血病51 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月6日。每项研究自行设定入选标准，由研究团队决定谁能参与。